Mohan Suresh, Pai Sara I, Bhattacharyya Neil
Department of Otology and Laryngology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, U.S.A.
Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, U.S.A.
Laryngoscope. 2017 Jun;127(6):1334-1338. doi: 10.1002/lary.26443. Epub 2017 Feb 1.
To analyze the impact of adjuvant radiation therapy (RT) on overall survival (OS) and disease-specific survival (DSS) in patients with verrucous carcinoma (VC) as compared to squamous cell carcinoma (SCC) of the oral cavity.
Cross-sectional population analysis.
Cases of nonmetastatic VC/SCC of the oral cavity were extracted from the Surveillance, Epidemiology, and End Results (SEER) database (1988-2013). Kaplan-Meier survivals, stratified according to T stage, were compared between VC and SCC for treatment with or without adjuvant RT.
A total of 18,819 VC/SCC cases were identified. There were 581 (3.1%) VC (mean age 69.6 years, 48.9% female) versus 18,238 (97.0%) SCC (mean age, 65.3, 37.1% female) patients. Verrucous carcinoma patients receiving surgery alone (N = 539) demonstrated a trend toward improved OS versus VC patients receiving surgery and RT (N = 40) (117.0 vs. 71.4 months, respectively, P = 0.119). There was a statistically significant improvement in DSS in VC patients receiving surgery alone (217.2 vs. 110.9 months, P = 0.05). Verrucous carcinoma patients treated with adjuvant RT demonstrated a trend toward a worse OS (71.4 vs. 93.0 months, P = 0.992) and DSS (110.9 vs. 162.3 months, P = 0.275) compared to SCC treated with adjuvant RT, suggesting a different biology and radiosensitivity between VC and SCC.
Verrucous carcinoma treated with adjuvant RT had a worse OS and DSS compared to both VC treated with surgery alone and SCC treated with surgery and adjuvant RT. Consideration should be given to surgical re-section rather than adjuvant RT in patients with positive margins or local recurrence.
2C. Laryngoscope, 127:1334-1338, 2017.
分析与口腔鳞状细胞癌(SCC)相比,辅助性放射治疗(RT)对疣状癌(VC)患者总生存期(OS)和疾病特异性生存期(DSS)的影响。
横断面人群分析。
从监测、流行病学和最终结果(SEER)数据库(1988 - 2013年)中提取口腔非转移性VC/SCC病例。根据T分期进行分层,比较VC和SCC接受或不接受辅助性RT治疗的Kaplan - Meier生存期。
共识别出18819例VC/SCC病例。其中有581例(3.1%)VC患者(平均年龄69.6岁,48.9%为女性),以及18238例(97.0%)SCC患者(平均年龄65.3岁,37.1%为女性)。单纯接受手术治疗的疣状癌患者(N = 539)与接受手术及RT治疗的VC患者(N = 40)相比,OS有改善趋势(分别为117.0个月和71.4个月,P = 0.119)。单纯接受手术治疗的VC患者DSS有统计学显著改善(217.2个月对110.9个月,P = 0.05)。与接受辅助性RT治疗的SCC相比,接受辅助性RT治疗的疣状癌患者OS(71.4个月对93.0个月,P = 0.992)和DSS(110.9个月对162.3个月,P = 0.275)有变差趋势,提示VC和SCC之间存在不同的生物学特性和放射敏感性。
与单纯接受手术治疗的VC以及接受手术和辅助性RT治疗的SCC相比,接受辅助性RT治疗的疣状癌患者OS和DSS更差。对于切缘阳性或局部复发的患者,应考虑手术切除而非辅助性RT。
2C。《喉镜》,2017年,第127卷,第1334 - 1338页